ERIVEDGE 150mg capsules EGIS ORIGINAL MEDICINE
Chemical substance: vismodegib
ATC code: L01XX43 • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Active substance
Results for the substance vismodegib
1 result
About this active substance
Vismodegib is a medication used for the treatment of advanced basal cell carcinoma, a type of skin cancer that cannot be treated with surgery or radiation therapy. It is a Hedgehog pathway inhibitor, which plays a critical role in the growth and survival of tumor cells. By blocking this pathway, vismodegib halts the proliferation of cancer cells.
The medication is administered orally, usually once daily, and the duration of treatment depends on the patient's response and tolerability. It is indicated for patients with locally advanced basal cell carcinoma as well as those with metastases.
Common side effects include nausea, fatigue, loss of appetite, muscle cramps, and hair loss. In rare cases, severe adverse reactions such as liver function impairment or allergic reactions may occur.
Patients receiving vismodegib should be regularly monitored for signs of toxicity and treatment efficacy. The medication represents an important therapeutic option for patients with advanced basal cell carcinoma, offering a chance to control disease progression.
The medication is administered orally, usually once daily, and the duration of treatment depends on the patient's response and tolerability. It is indicated for patients with locally advanced basal cell carcinoma as well as those with metastases.
Common side effects include nausea, fatigue, loss of appetite, muscle cramps, and hair loss. In rare cases, severe adverse reactions such as liver function impairment or allergic reactions may occur.
Patients receiving vismodegib should be regularly monitored for signs of toxicity and treatment efficacy. The medication represents an important therapeutic option for patients with advanced basal cell carcinoma, offering a chance to control disease progression.